Rituximab as the first-line treatment in newly diagnosed systemic lupus erythematosus
In patients with newly diagnosed moderate-to-severe SLE, upfront treatment with RTX was associated with improved clinical outcomes compared to conventional immunosuppressive therapy in terms of achieving low disease activity or remission by 12 months.
Authors
- Liling Zhao (ORCID: https://orcid.org/0000-0003-0631-9162)
- Jiajia Jin
- Shuang Ye (ORCID: https://orcid.org/0000-0002-5257-5768)
- Huihua Ding (ORCID: https://orcid.org/0000-0002-7530-8953)
- Qiong Fu (ORCID: https://orcid.org/0000-0001-5873-6422)
- Shaoying Yang (ORCID: https://orcid.org/0000-0001-9091-4209)
- Wanlong Wu (ORCID: https://orcid.org/0000-0003-2727-7950)
- Liqin Yu (ORCID: https://orcid.org/0000-0002-3602-531X)
- Haiting Wang (ORCID: https://orcid.org/0000-0002-5214-4458)
- Nan Shen
Institutions
- Renji Hospital (CN)
- National Institute of Dental and Craniofacial Research (US)
- Suzhou Kowloon Hospital (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-06-20
- DOI
- https://doi.org/10.3389/fimmu.2025.1599473
- Citations
- 4
- Primary Topic
- Systemic Lupus Erythematosus Research
- Type
- article
- Field-Weighted Citation Impact
- 6.67